BioMarin Fails to Win Approval for Drug to Treat Duchenne

  • FDA told company it didn't hit `substantial evidence' standard
  • Stock declines, analyst said investors had expected rejection

BioMarin Pharmaceutical Inc. failed to win U.S. approval for a drug to treat Duchenne muscular dystrophy, a deadly genetic disease that usually affects young boys.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.